Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Neuroscientific Biopharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $60.98 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 143.47 million
Earnings per share -0.028
Dividend per share N/A
Year To Date Return 40.00%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Neuroscientific Biopharmaceuticals Ltd (ASX: NSB)
Latest News

NSB ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Neuroscientific Biopharmaceuticals Ltd

Neuroscientific Biopharmaceuticals Ltd is an Australian based biotechnology company. The company is engaged in the development of diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies.

NSB Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
16 Sep 2021 $0.43 $0.03 7.50% 1,414,605 $0.40 $0.46 $0.40
15 Sep 2021 $0.40 $0.05 14.29% 1,500,195 $0.36 $0.41 $0.36
14 Sep 2021 $0.35 $-0.01 -2.82% 295,146 $0.36 $0.36 $0.35
13 Sep 2021 $0.36 $0.00 0.00% 83,659 $0.36 $0.36 $0.36
10 Sep 2021 $0.36 $-0.02 -5.41% 304,089 $0.37 $0.37 $0.36
09 Sep 2021 $0.37 $0.01 2.74% 401,646 $0.36 $0.37 $0.36
08 Sep 2021 $0.37 $0.01 2.78% 249,382 $0.37 $0.37 $0.36
07 Sep 2021 $0.36 $0.00 0.00% 818,207 $0.37 $0.38 $0.36
06 Sep 2021 $0.36 $0.04 12.50% 442,371 $0.33 $0.36 $0.33
03 Sep 2021 $0.32 $0.01 3.17% 326,818 $0.33 $0.34 $0.32
02 Sep 2021 $0.32 $0.01 3.23% 233,366 $0.32 $0.32 $0.31
01 Sep 2021 $0.31 $-0.03 -8.82% 173,056 $0.34 $0.34 $0.31
31 Aug 2021 $0.34 $0.01 3.03% 1,497,184 $0.36 $0.37 $0.31
30 Aug 2021 $0.33 $0.00 0.00% 3,767 $0.33 $0.33 $0.33
27 Aug 2021 $0.33 $0.01 3.13% 239,245 $0.32 $0.33 $0.32
26 Aug 2021 $0.32 $0.01 3.23% 516,738 $0.32 $0.32 $0.31
25 Aug 2021 $0.31 $0.00 0.00% 104,528 $0.32 $0.32 $0.31
24 Aug 2021 $0.31 $0.01 3.33% 175,387 $0.31 $0.32 $0.31
23 Aug 2021 $0.30 $-0.03 -9.23% 983,019 $0.33 $0.34 $0.30
20 Aug 2021 $0.33 $0.01 3.17% 1,451,687 $0.32 $0.35 $0.31
19 Aug 2021 $0.32 $0.03 10.34% 1,941,825 $0.32 $0.33 $0.30
18 Aug 2021 $0.29 $0.00 0.00% 50,331 $0.29 $0.29 $0.29
17 Aug 2021 $0.29 $-0.01 -3.39% 80,000 $0.29 $0.29 $0.29

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
09 Jul 2021 Paul Rennie Buy 300 $99,672
On-market trade.
18 May 2021 Matthew Liddelow Buy 50 $12,154
On-market trade.
13 May 2021 Brian Leedman Buy 123 $27,806
On-market trade.
13 May 2021 Stephen Quantrill Buy 30 $6,769
On-market trade. As per announcement on 18/05/2021.
01 Mar 2021 Brian Leedman Sell 100 $370
On-market trade.
25 Feb 2021 Anton Uvarov Exercise 400 $80,000
Exercise of options.
25 Feb 2021 Anton Uvarov Buy 400 $80,000
Exercise of options.
25 Feb 2021 Anton Uvarov Exercise 400 $80,000
Exercise of options.
25 Feb 2021 Anton Uvarov Sell 250 $3,647
On-market trade.
18 Feb 2021 Brian Leedman Buy 600 $120,000
Exercise of options.
18 Feb 2021 Brian Leedman Sell 300 $74,498
On-market trade.
18 Feb 2021 Brian Leedman Exercise 600 $120,000
Exercise of options.
15 Jan 2021 Stephen Quantrill Issued 500 $125,000
Director remuneration.
15 Jan 2021 Matthew Liddelow Issued 1 $300,000
Director remuneration. As per announcement on 15/01/2021.
15 Jan 2021 Anton Uvarov Issued 800 $200,000
Director remuneration. As per announcement on 15/01/2021.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Paul Rennie Non-Executive ChairmanNon-Executive Director Jun 2021
Mr Rennie has experience in global drug development and pre-clinical and clinical trials. Mr Rennie is the Chief Executive Officer and a founder of ASX-listed Paradigm Biopharmaceuticals Ltd ("Paradigm") (ASX: PAR) - a late-stage drug development company. Mr Rennie is also a former Chief Operating Officer of Mesoblast Ltd (ASX: MSB).
Dr Anton Uvarov Executive Director Sep 2017
Dr Uvarov has experience as an equity analyst in the healthcare industry with a focus on the biotechnology sector, both domestically and internationally. Prior to moving to Australia, he was with Citigroup Global Markets where he spent two years as a member of a New York based biotechnology team that was continuously ranked top 4 for Biotechnology in the All-America Institutional Investor survey. Dr Uvarov's scientific expertise and company knowledge spreads across a variety of therapeutic areas and spectrum of market capitalizations with his particular interest in early stage biotechnology companies.
Mr Stephen Quantrill Non-Executive Director Feb 2015
Mr Quantrill has over 20 years experience in multifaceted roles in business ownership, corporate advisory, and company directorship with experience as a business executive and private equity professional. Mr Quantrill is the Executive Chairman of McRae Investments, the Clough family private investment company, Executive Chairman of the Indo-Pacific Group, Chairman of Pedco Engineering, Executive Director of Colomi Iron, and Non-Executive Director of Twinza Oil.
Mr Matthew Liddelow Chief Executive OfficerManaging Director Feb 2018
Mr Liddelow Has over 12 years experience in the commercialisation of biotechnology, medical devices and pharmaceuticals. Mr Liddelow has been involved in a number of start-up companies, including medical device company Medevco Pty Ltd, which was acquired by Allied Healthcare Group Ltd (now Ademus Ltd). While employed by multi-national pharmaceutical company Astra Zeneca, Mr Liddelow gained first-hand experience in the development, marketing and product launch of cardio vascular and respiratory related medications. In 2014, Mr Liddelow founded Enhanced Biomedical Pty Ltd of which he was Managing Director.
Ms Abby Macnish Niven Company Secretary Apr 2020
-
Abby Macnish Niven Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
McRae Technology Pty Ltd 13,841,670 23.45%
McRae Investments Pty Ltd 5,000,000 8.47%
UTAS Holdings Pty Ltd 2,820,896 4.78%
Parklands Super Fund 1,690,000 2.86%
Patrick John McHale 1,561,729 2.65%
McCusker Holdings Pty Ltd 1,150,000 1.95%
Yodambao Pty Ltd 1,041,667 1.76%
The University of Western Australia 933,334 1.58%
Hosanda Corporation Pty Limited 650,000 1.10%
Dr Roger Douglas Pryde Paterson 600,000 1.02%
Trung Van Ly 590,000 1.00%
McCusker Holdings Pty Ltd I 500,000 0.85%
Slam Consulting Pty Ltd 500,000 0.85%
GCN Investments Pty Ltd 482,500 0.82%
RDP Paterson Superfund Pty Ltd 455,000 0.77%
Yung Liu 430,000 0.73%
Bnp Paribas Nominees Pty Ltd 425,584 0.72%
Underlex Pty Ltd 400,000 0.68%
Wilk Holdings Pty Ltd 400,000 0.68%
Janakan Krishnarajah 375,000 0.64%

Profile

since

Note